Our news section contains recent news on neuroendocrine tumors, upcoming NANETS events and information, and people in our community. Have a suggestion? Please click here to contact us.

Neuroendocrine Tumor Research Foundation Awards Six Grants

The Neuroendocrine Tumor Research Foundation (NETRF) awarded six new research grants totaling $1.85 million to leading academic institutions around the world. The goal of the funding is to improve current treatments for neuroendocrine tumors (NETs), an uncommon and poorly understood cancer, which occurs in the body’s hormone-producing cells.

Susanne Schaffert joins Advanced Accelerator Applications Division of Novartis

Susanne Schaffert, PhD was appointed Chairperson and President of Advanced Accelerator Applications (AAA) in January 2018, following the completion of a tender offer for the company by Novartis.

Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a Novartis company and leader in nuclear medicine theragnostics, today announced that it has received US Food and Drug Administration (FDA) approval of its new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate*) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

Stanford University NET Fellowship

Stanford University School of Medicine has established a new one-year Neuroendocrine Tumor (NET) Fellowship under the direction of NANETS Board Member, Dr. Pamela Kunz. The increasing incidence and prevalence of NET disease combined with the complex multidisciplinary care required by NET patients, Stanford University developed this focused fellowship program to fill a need.

2017 Basic Translational Science Investigator

NANETS congratulates Brian Untch, MD of Memorial Sloan Kettering Cancer Center as the NANETS 2017 Basic Translational Science In

2017 NANETS Clinical Investigator Scholarship

NANETS congratulates Etay Ziv, MD, PhD of Memorial Sloan Kettering Cancer Center as the 2017 NANETS Clinical Investigator Scholarship recipient.  The NCIS award focuses on supporting a clinical project as well as the investigator's potential to make future clinical contributions to the neuroendo

Novartis Announces the Planned Acquisition of Advanced Accelerator Applications

Novartis announced that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera® (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors (NETs). Radiopharmaceuticals, such as Lutathera, are unique medicinal formulations containing radioisotopes which are used clinically for both diagnosis and therapy. The transaction would strengthen Novartis' oncology presence with both near-term product launches as well as a new technology platform with potential applications across a number of oncology early development programs.

NANETS2017 Registration Update

Dear NANETS Members and Colleagues,

We are so grateful to everyone interested in attending the 10th Annual NANETS Symposium, October 19-21, 2017 in Philadelphia, PA. We have exceeded last year by over 180 registrants

For the first time ever, the annual NANETS Symposium has SOLD OUT. Due to hotel capacity rules and fire codes we unfortunately cannot accommodate any more registrants, including any walk-up registrations.

NANETS to Present Basic/Translational Science Investigator Award

The North American Neuroendocrine Tumor Society (NANETS) is pleased to announce the Neuroendocrine Tumor Research Foundation (NETRF) Board of Directors has approved funding for the Basic/Translational Science Investigator (BTSI) Award for 2017 presented by NANETS. The 2017 award will be announced at the NANETS 10th annual symposium, to be held October 19-21 in Philadelphia, PA.

NANETS to Present Clinical Investigator Scholarship

The North American Neuroendocrine Tumor Society (NANETS) will present the NANETS Clinical Investigator Scholarship at the organization’s 10th annual symposium, to be held October 19-21 in Philadelphia, PA.